Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

被引:60
|
作者
Arban, R
Maraia, G
Brackenborough, K
Winyard, L
Wilson, A
Gerrard, P
Large, C
机构
[1] GlaxoSmithKline SpA, Dept Biol, Psychiat CEDD, I-37135 Verona, Italy
[2] GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal CEDD, Harlow, Essex, England
关键词
bipolar disorder; anticonvulsant; hyperactivity; seizure; animal model;
D O I
10.1016/j.bbr.2004.08.015
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Bipolar disorder is a psychiatric condition characterised by episodes of mania, depression, and underlying mood instability. Anticonvulsant drugs have an established place in the treatment of the disorder, but identifying novel drugs in this class is complicated by the absence of validated animal models. We have evaluated the efficacy of three anticonvulsant mood stabilising drugs (lamotrigine, valproate, and carbamazepine) in a model of mania, in which hyperactivity is induced by the combination Of D-amphetamine and chlordiazepoxide. All three drugs were effective at preventing the hyperactivity. Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole. Lamotrigine was equipotent in the two models. However, the complex pharmacology of the D-amphetamine/chlordiazepoxide model means that there may be several mechanisms by which hyperactivity can be reduced, and these may have more or less relevance to the treatment of bipolar disorder. To address this issue, we also evaluated effects of the three anticonvulsants on baseline locomotion, on activity in the presence of chlordiazepoxide alone, or on activity induced by D-amphetamine alone. Based on the results, we propose that hyperactivity induced by D-amphetamine/chlordiazepoxide may arise through dopaminergic drive coupled with disinhibition caused by low doses of the benzodiazepine. The efficacy of lamotrigine may then arise through a reduction in neuronal excitability or increased glutamate transmission, these latter a consequence of the disinhibition. Carbamazepine may also reduce excitability and glutamate release, but its broader pharmacology, manifested by sedation at higher doses complicates interpretation of its efficacy and reflects its poorer tolerability in the clinic. Valproate may be effective, at least in part, through an enhancement of GABAergic transmission. The predictive validity of the D-amphetamine/chlordiazepoxide model for efficacy in bipolar disorder remains to be established, and research with a wider range of clinically tested drugs is warranted to help validate the model further. In the meantime, the model may be useful for distinguishing novel anticonvulsant drugs with different mechanisms of action. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 50 条
  • [21] Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling taskRelevance to mania
    Jordy van Enkhuizen
    Mark A. Geyer
    Jared W. Young
    Psychopharmacology, 2013, 225 : 661 - 674
  • [22] Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: A novel experimental model of pharmacoresistant epilepsy
    Srivastava, Ajay K.
    Alex, Anitha B.
    Wilcox, Karen S.
    White, H. Steve
    EPILEPSIA, 2013, 54 (07) : 1186 - 1194
  • [23] Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels
    Ulrich, ML
    Rotzinger, S
    Asghar, SJ
    Jurasz, P
    Tanay, VA
    Dunn, SMJ
    Radomski, M
    Greenshaw, A
    Silverstone, PH
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2003, 28 (02): : 115 - 125
  • [24] Differential effects of lithium isotopes in a ketamine-induced hyperactivity model of mania
    Ettenberg, Aaron
    Ayala, Kathy
    Krug, Jacob T.
    Collins, Lisette
    Mayes, Matthew S.
    Fisher, Matthew P. A.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2020, 190
  • [25] Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of Mania
    Jornada, Luciano K.
    Valvassori, Samira S.
    Steckert, Amanda V.
    Moretti, Morgana
    Mina, Francielle
    Ferreira, Camila L.
    Arent, Camila O.
    Dal-Pizzol, Felipe
    Quevedo, Joao
    JOURNAL OF PSYCHIATRIC RESEARCH, 2011, 45 (02) : 162 - 168
  • [26] Antimyoclonic and neuroprotective effects of lamotrigine in an animal model of cardiac arrest
    Kanthasamy, AG
    Tith, T
    Nguyen, B
    Tran, A
    Truong, DD
    RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 1999, 15 (01) : 45 - 56
  • [27] Effects of mood stabilizers on DNA damage in an animal model of mania
    Andreazza, Ana Cristina
    Kauer-Sant'Anna, Marcia
    Frey, Benicio N.
    Stertz, Laura
    Zanotto, Caroline
    Ribeiro, Leticia
    Giasson, Karine
    Valvassori, Samira S.
    Reus, Gislaine Z.
    Salvador, Mirian
    Quevedo, Joao
    Goncalves, Carlos A.
    Kapczinski, Flavio
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2008, 33 (06): : 516 - 524
  • [28] Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain
    Jornada, Luciano K.
    Moretti, Morgana
    Valvassori, Samira S.
    Ferreira, Camila L.
    Padilha, Peterson T.
    Arent, Camila O.
    Fries, Gabriel R.
    Kapczinski, Flavio
    Quevedo, Joao
    JOURNAL OF PSYCHIATRIC RESEARCH, 2010, 44 (08) : 506 - 510
  • [29] Effects of ouabain on cytokine/chemokine levels in an animal model of mania
    Tonin, Paula T.
    Valvassori, Samira S.
    Lopes-Borges, Jessica
    Mariot, Edemilson
    Varela, Roger B.
    Teixeira, Antonio Lucio
    Quevedo, Joao
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 276 (1-2) : 236 - 239
  • [30] Behavioral and neurochemical effects of sodium butyrate in an animal model of mania
    Moretti, Morgana
    Valvassori, Samira S.
    Varela, Roger B.
    Ferreira, Camila L.
    Rochi, Natalia
    Benedet, Joana
    Scaini, Giselli
    Kapczinski, Flavio
    Streck, Emilio L.
    Zugno, Alexandra I.
    Quevedo, Joao
    BEHAVIOURAL PHARMACOLOGY, 2011, 22 (08): : 766 - 772